These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37468946)

  • 21. Structure, dynamics, and binding thermodynamics of the v-Src SH2 domain: implications for drug design.
    Taylor JD; Ababou A; Fawaz RR; Hobbs CJ; Williams MA; Ladbury JE
    Proteins; 2008 Dec; 73(4):929-40. PubMed ID: 18536014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-affinity Src-SH2 ligands which do not activate Tyr(527)-phosphorylated Src in an experimental in vivo system.
    Mandine E; Jean-Baptiste V; Vayssière B; Gofflo D; Bénard D; Sarubbi E; Deprez P; Baron R; Superti-Furga G; Lesuisse D
    Biochem Biophys Res Commun; 2002 Oct; 298(2):185-92. PubMed ID: 12387813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The specificity of the N-terminal SH2 domain of SHP-2 is modified by a single point mutation.
    Huyer G; Ramachandran C
    Biochemistry; 1998 Mar; 37(9):2741-7. PubMed ID: 9485424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative mode of binding to phosphotyrosyl peptides by Src homology-2 domains.
    Qin C; Wavreille AS; Pei D
    Biochemistry; 2005 Sep; 44(36):12196-202. PubMed ID: 16142918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
    Zhou P; Hou S; Bai Z; Li Z; Wang H; Chen Z; Meng Y
    Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1122-1131. PubMed ID: 28754059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterizing SH2 Domain Specificity and Network Interactions Using SPOT Peptide Arrays.
    Liu BA
    Methods Mol Biol; 2017; 1555():357-373. PubMed ID: 28092043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of the Src SH2 domain to phosphopeptides is determined by residues in both the SH2 domain and the phosphopeptides.
    Bibbins KB; Boeuf H; Varmus HE
    Mol Cell Biol; 1993 Dec; 13(12):7278-87. PubMed ID: 7504171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands.
    Gay B; Furet P; García-Echeverría C; Rahuel J; Chène P; Fretz H; Schoepfer J; Caravatti G
    Biochemistry; 1997 May; 36(19):5712-8. PubMed ID: 9153411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct determination of the sequence recognition requirements of the SH2 domains of SH-PTP2.
    Huyer G; Li ZM; Adam M; Huckle WR; Ramachandran C
    Biochemistry; 1995 Jan; 34(3):1040-9. PubMed ID: 7530043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conformational basis for SH2-Tyr(P)527 binding in Src inactivation.
    Ayrapetov MK; Wang YH; Lin X; Gu X; Parang K; Sun G
    J Biol Chem; 2006 Aug; 281(33):23776-84. PubMed ID: 16790421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folding and Binding Mechanisms of the SH2 Domain from Crkl.
    Nardella C; Toto A; Santorelli D; Pagano L; Diop A; Pennacchietti V; Pietrangeli P; Marcocci L; Malagrinò F; Gianni S
    Biomolecules; 2022 Jul; 12(8):. PubMed ID: 35892324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SH2 domain from the tyrosine kinase Fyn in complex with a phosphotyrosyl peptide reveals insights into domain stability and binding specificity.
    Mulhern TD; Shaw GL; Morton CJ; Day AJ; Campbell ID
    Structure; 1997 Oct; 5(10):1313-23. PubMed ID: 9351806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diversity in peptide recognition by the SH2 domain of SH2B1.
    McKercher MA; Guan X; Tan Z; Wuttke DS
    Proteins; 2018 Feb; 86(2):164-176. PubMed ID: 29127727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superbinder SH2 domains act as antagonists of cell signaling.
    Kaneko T; Huang H; Cao X; Li X; Li C; Voss C; Sidhu SS; Li SS
    Sci Signal; 2012 Sep; 5(243):ra68. PubMed ID: 23012655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the Brk SH3 domain in substrate recognition.
    Qiu H; Miller WT
    Oncogene; 2004 Mar; 23(12):2216-23. PubMed ID: 14676834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-src: identification of phosphorylation sites and c-src SH2 domain binding sites.
    Lombardo CR; Consler TG; Kassel DB
    Biochemistry; 1995 Dec; 34(50):16456-66. PubMed ID: 8845374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative modes of tyrosyl phosphopeptide binding to a Src family SH2 domain: implications for regulation of tyrosine kinase activity.
    Ladbury JE; Hensmann M; Panayotou G; Campbell ID
    Biochemistry; 1996 Aug; 35(34):11062-9. PubMed ID: 8780508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The amino-terminal Src homology 2 domain of phospholipase C gamma 1 is essential for TCR-induced tyrosine phosphorylation of phospholipase C gamma 1.
    Stoica B; DeBell KE; Graham L; Rellahan BL; Alava MA; Laborda J; Bonvini E
    J Immunol; 1998 Feb; 160(3):1059-66. PubMed ID: 9570517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1.
    Pei D; Wang J; Walsh CT
    Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1141-5. PubMed ID: 8577729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conformational determinants of phosphotyrosine peptides complexed with the Src SH2 domain.
    Nachman J; Gish G; Virag C; Pawson T; Pomès R; Pai E
    PLoS One; 2010 Jun; 5(6):e11215. PubMed ID: 20574521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.